| 2.98 0.06 (2.05%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.67 | 1-year : | 3.97 |
| Resists | First : | 3.14 | Second : | 3.4 |
| Pivot price | 2.9  |
|||
| Supports | First : | 2.74 | Second : | 2.27 |
| MAs | MA(5) : | 2.92 |
MA(20) : | 2.95 |
| MA(100) : | 3.05 |
MA(250) : | 3.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38 |
D(3) : | 37.6 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 6.44 | Low : | 2.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALT ] has closed below upper band by 27.2%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.1 - 3.12 | 3.12 - 3.13 |
| Low: | 2.86 - 2.88 | 2.88 - 2.89 |
| Close: | 2.89 - 2.92 | 2.92 - 2.95 |
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Tue, 28 Jul 2026
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study - Benzinga
Tue, 28 Jul 2026
Altimmune (ALT) Reports Positive Phase 2 RECLAIM Trial Results, Market Reflects Cautious Optimism - GuruFocus
Tue, 28 Jul 2026
ALT Stock Holds Range As Cash Runway Supports Speculative Trading - StocksToTrade
Tue, 28 Jul 2026
Altimmune (ALT) Reports Positive Phase 2 Results for Pemvidutide in Alcohol Use Disorder - GuruFocus
Tue, 28 Jul 2026
ALT Stock Holds Range As Traders Weigh Cash And Losses - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 194 (M) |
| Held by Insiders | 1.642e+008 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 41,930 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.61e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -267 % |
| Return on Assets (ttm) | 247.2 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | 36000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -178.13 |
| EBITDA (p.s.) | -2.75208e+008 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 32.6 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.32 |
| Dividend | 0 |
| Forward Dividend | 4.824e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|